GDS Holdings (GDS)
(Delayed Data from NSDQ)
$16.12 USD
-0.05 (-0.28%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.10 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.12 USD
-0.05 (-0.28%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.10 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
GDS HOLDINGS (GDS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
GDS HOLDINGS (GDS) delivered earnings and revenue surprises of -27.27% and 7.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Business Services Stocks' Earnings on Nov 13: SWCH and GDS
by Zacks Equity Research
The Business Services sector benefits from economic growth. Investors interested in stocks from this sector can watch out for third-quarter 2018 earnings reports of SWCH and GDS.
GDS HOLDINGS (GDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
GDS HOLDINGS (GDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings
by Zacks Equity Research
Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings
5 Stocks to Buy as New Analysts Show Interest
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.